Malgorzata Krajewska, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclin-Dependent Kinases | 2 | 2019 | 675 | 0.700 |
Why?
|
| DNA Damage | 2 | 2019 | 2467 | 0.410 |
Why?
|
| Chromosomal Instability | 1 | 2010 | 165 | 0.380 |
Why?
|
| DNA Repair | 2 | 2019 | 2059 | 0.380 |
Why?
|
| Mitosis | 2 | 2013 | 1255 | 0.350 |
Why?
|
| Xenopus Proteins | 1 | 2010 | 454 | 0.320 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1105 | 0.270 |
Why?
|
| Adrenergic Agents | 1 | 2022 | 69 | 0.230 |
Why?
|
| Evolution, Molecular | 1 | 2010 | 1963 | 0.210 |
Why?
|
| Drosophila Proteins | 1 | 2010 | 1768 | 0.200 |
Why?
|
| Polyadenylation | 1 | 2019 | 113 | 0.170 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2019 | 445 | 0.140 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 962 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1174 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 1637 | 0.130 |
Why?
|
| Pilocarpine | 2 | 2004 | 69 | 0.130 |
Why?
|
| Timolol | 2 | 2004 | 53 | 0.130 |
Why?
|
| Osteosarcoma | 1 | 2019 | 890 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 1116 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2015 | 1270 | 0.100 |
Why?
|
| Thiophenes | 2 | 2004 | 601 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2019 | 5535 | 0.090 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2004 | 659 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2019 | 8738 | 0.080 |
Why?
|
| Xenopus laevis | 1 | 2010 | 1013 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1899 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 16943 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2004 | 1930 | 0.060 |
Why?
|
| Intraocular Pressure | 2 | 2004 | 1165 | 0.050 |
Why?
|
| Drosophila melanogaster | 1 | 2010 | 1779 | 0.050 |
Why?
|
| Genomics | 1 | 2015 | 5333 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 8674 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 758 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 2064 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 817 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 2842 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 514 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2022 | 2611 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 775 | 0.030 |
Why?
|
| Humans | 8 | 2022 | 715124 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 588 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2004 | 1941 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3071 | 0.020 |
Why?
|
| Cytokines | 1 | 2022 | 7225 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 170726 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 20515 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 1711 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2015 | 2614 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 3020 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16371 | 0.020 |
Why?
|
| Miotics | 1 | 2004 | 8 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5482 | 0.010 |
Why?
|
| Ocular Hypertension | 1 | 2003 | 189 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 3503 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2004 | 11900 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 13292 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 2004 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1219 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9521 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 1230 | 0.010 |
Why?
|
| Models, Biological | 1 | 2013 | 9895 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 12567 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 80995 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23973 | 0.010 |
Why?
|
| Female | 3 | 2019 | 377334 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2004 | 62186 | 0.000 |
Why?
|
| Middle Aged | 2 | 2004 | 214871 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2003 | 51181 | 0.000 |
Why?
|
| Male | 2 | 2004 | 351081 | 0.000 |
Why?
|
| Aged | 1 | 2004 | 162674 | 0.000 |
Why?
|